Solvonis Therapeutics: Redefining Treatment for Alcohol Use Disorder Through Capital-Efficient Innovation

In this episode of WTR Healthcare Happenings, Anthony Tennyson, CEO and Co-Founder of Solvonis Therapeutics (LSE: SVNS | OTC: SLVNF), joins host Tim Gerdeman, Vice Chair and Co-Founder of Water Tower Research, and analyst Robert Sassoon.The clinical-stage, UK-listed company (LSE: SVNS) focuses on developing novel medicines for high-burden CNS disorders, with its current focus primarily on Alcohol Use Disorder (AUD). Our discussion delves into  Solvonis' lead clinical programs, SVN-001 and SVN-002, that aim to address this major societal problem. Tennyson highlights anticipated upcoming milestones and outlines Solvonis' capital-efficient business model and financial strategy to advance its AUD programs to commercialization.